UnitedHealth
US.UNH
397.14
-3.80
-0.95%
UnitedHealth
397.14
-3.80
-0.95%
Collector offline (last heartbeat: 19234s ago)
· 2026-09-04 20:02
Pre-market
397.20
-0.93%
After-hours
396.85
-0.07%
Overnight
400.55
-0.10%
Revenue annual, last 8 years
Latest year +11.81% YoY
Margins
- Gross margin
- 18.53%
- Operating margin
- 4.24%
- Net margin
- 2.69%
Key ratios & quality
- Enterprise value
- 406.74B
- Altman Z-Score
- 3.01
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.01, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 226.25B | 242.16B | 257.14B | 287.60B | 324.16B | 371.62B | 400.28B | 447.57B |
| Gross profit | 53.85B | 57.60B | 67.00B | 69.65B | 79.62B | 90.96B | 89.40B | 82.92B |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 17.34B | 19.69B | 22.41B | 23.97B | 28.44B | 32.36B | 32.29B | 18.96B |
| Pretax profit | 15.94B | 17.98B | 20.74B | 22.31B | 26.34B | 29.11B | 20.07B | 14.70B |
| Tax | 3.56B | 3.74B | 4.97B | 4.58B | 5.70B | 5.97B | 4.83B | 1.89B |
| Net profit | 12.38B | 14.24B | 15.77B | 17.73B | 20.64B | 23.14B | 15.24B | 12.81B |
| Basic EPS | 12 | 15 | 16 | 18 | 21 | 24 | 16 | 13 |
| Diluted EPS | 12.19 | 14.33 | 16.03 | 18.08 | 21.18 | 23.86 | 15.51 | 13.23 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 109.58B | 111.62B | 113.16B | 113.22B | 111.72B | 112.03B |
| Gross profit | 23.77B | 20.01B | 20.64B | 18.49B | 25.41B | 23.30B |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 9.12B | 5.15B | 4.32B | 380.00M | 8.99B | 7.99B |
| Pretax profit | 8.11B | 4.08B | 3.23B | -720.00M | 7.96B | 6.97B |
| Tax | 1.63B | 510.00M | 686.00M | -938.00M | 1.48B | 1.30B |
| Net profit | 6.47B | 3.57B | 2.54B | 218.00M | 6.48B | 5.67B |
| Basic EPS | 7 | 4 | 3 | 0 | 7 | 6 |
| Diluted EPS | 6.85 | 3.74 | 2.59 | 0.01 | 6.90 | 6.04 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 38.69B | 42.63B | 53.72B | 61.76B | 69.07B | 78.44B | 85.78B | 90.58B |
| Cash & ST investments | 14.32B | 14.25B | 19.78B | 23.91B | 27.91B | 29.63B | 29.11B | 28.12B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 152.22B | 173.89B | 197.29B | 212.21B | 245.71B | 273.72B | 298.28B | 309.58B |
| Total current liabilities | 53.21B | 61.78B | 72.42B | 78.29B | 89.24B | 99.05B | 103.77B | 114.90B |
| Short-term debt | 1.97B | 3.87B | 4.82B | 3.62B | 3.11B | 4.27B | 4.55B | 6.07B |
| Long-term debt | 34.58B | 36.81B | 38.65B | 42.38B | 54.51B | 58.26B | 72.36B | 72.32B |
| Total liabilities | 95,994,000,000.00 | 111,727,000,000.00 | 126,750,000,000.00 | 135,727,000,000.00 | 159,358,000,000.00 | 174,801,000,000.00 | 195,687,000,000.00 | 207,883,000,000.00 |
| Total equity | 56.23B | 62.16B | 70.54B | 76.48B | 86.35B | 98.92B | 102.59B | 101.70B |
| Retained earnings | 55.85B | 61.18B | 69.30B | 77.13B | 86.16B | 95.77B | 96.04B | 95.60B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 96.29B | 93.70B | 95.07B | 90.58B | 91.13B | 86.86B |
| Cash & ST investments | 34.29B | 32.02B | 30.61B | 28.12B | 31.23B | 31.47B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 309.79B | 308.57B | 315.27B | 309.58B | 312.64B | 309.73B |
| Total current liabilities | 113.47B | 110.78B | 115.53B | 114.90B | 114.12B | 111.82B |
| Short-term debt | 9.99B | 5.70B | 7.74B | 6.07B | 6.48B | 3.83B |
| Long-term debt | 71.29B | 73.50B | 72.40B | 72.32B | 71.44B | 69.50B |
| Total liabilities | 204,621,000,000.00 | 203,789,000,000.00 | 209,456,000,000.00 | 207,883,000,000.00 | 207,325,000,000.00 | 203,778,000,000.00 |
| Total equity | 105.17B | 104.78B | 105.81B | 101.70B | 105.32B | 105.95B |
| Retained earnings | 97.93B | 97.25B | 97.60B | 95.60B | 99.88B | 100.96B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 15.71B | 18.46B | 22.17B | 22.34B | 26.21B | 29.07B | 24.20B | 19.70B |
| Depreciation & amortization | 2.43B | 2.72B | 2.89B | 3.10B | 3.40B | 3.97B | 4.10B | 4.36B |
| Free cash flow | 13.65B | 16.39B | 20.12B | 19.89B | 23.40B | 25.68B | 20.71B | 16.08B |
| Dividends paid | -3.32B | -3.93B | -4.58B | -5.28B | -5.99B | -6.76B | -7.53B | -7.92B |
| Stock buybacks / issuance | -3.66B | -4.46B | -2.81B | -3.65B | -5.75B | -6.65B | -7.15B | -4.72B |
| Ending cash balance | 10.87B | 10.99B | 16.92B | 21.38B | 23.37B | 25.43B | 25.31B | 24.37B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 5.46B | 7.19B | 5.95B | 1.11B | 8.91B | 11.05B |
| Depreciation & amortization | 1.06B | 1.08B | 1.10B | 1.12B | 1.03B | 1.04B |
| Free cash flow | 4.56B | 6.30B | 5.06B | 160.00M | 8.15B | 10.25B |
| Dividends paid | -1.91B | -2.00B | -2.00B | -2.00B | -2.01B | -2.09B |
| Stock buybacks / issuance | -2.64B | -2.32B | 222.00M | 24.00M | 231.00M | -1.52B |
| Ending cash balance | 30.72B | 28.60B | 27.21B | 24.37B | 28.00B | 28.59B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | 24.10 | 25.32 | 25.02 | 25.19 | 26.91 | 26.88 | 15.88 | 12.91 |
| ROA % | 8.23 | 8.49 | 8.30 | 8.44 | 8.79 | 8.62 | 5.04 | 3.97 |
| ROIC % | 15.59 | 16.28 | 16.09 | 16.41 | 17.19 | 17.41 | 10.83 | 9.09 |
| 5-year avg ROE % | 20.61 | 22.19 | 23.69 | 24.83 | 25.31 | 25.86 | 23.98 | 21.55 |
| EBIT margin % | 7.67 | 8.13 | 8.71 | 8.33 | 8.77 | 8.71 | 5.99 | 4.18 |
| FCF / sales % | 6.03 | 6.77 | 7.83 | 6.92 | 7.22 | 6.91 | 5.17 | 3.59 |
| Current ratio | 0.73 | 0.69 | 0.74 | 0.79 | 0.77 | 0.79 | 0.83 | 0.79 |
| Quick ratio | 0.48 | 0.42 | 0.62 | 0.66 | 0.65 | 0.69 | 0.75 | 0.70 |
| Debt / assets | 70.71 | 70.60 | 66.37 | 64.11 | 74.09 | 70.46 | 83.00 | 83.30 |
| LT debt / equity | 66.89 | 63.89 | 59.01 | 59.06 | 70.09 | 65.64 | 78.09 | 76.85 |
| Interest coverage | 12.39 | 11.55 | 13.47 | 14.44 | 13.59 | 9.97 | 6.14 | 4.67 |
| Revenue CAGR (3Y) % | 12.93 | 9.42 | 8.53 | 8.33 | 10.21 | 13.06 | 11.65 | 11.35 |
| Net income CAGR (3Y) % | 27.28 | 25.41 | 13.42 | 12.98 | 13.29 | 13.26 | -5.89 | -15.69 |
| FCF CAGR (3Y) % | 18.59 | 26.54 | 20.25 | 13.37 | 12.60 | 8.47 | 1.35 | -11.77 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 24.33 | 23.14 | 18.48 | 12.91 | 12.49 | 14.62 |
| ROA % | 7.44 | 7.16 | 5.72 | 3.97 | 3.87 | 4.57 |
| ROIC % | 15.10 | 14.60 | 12.01 | 9.09 | 8.82 | 10.10 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 7.86 | 7.26 | 6.03 | 4.18 | 4.12 | 4.74 |
| FCF / sales % | 6.06 | 5.98 | 3.99 | 3.59 | 4.37 | 5.25 |
| Current ratio | 0.85 | 0.85 | 0.82 | 0.79 | 0.80 | 0.78 |
| Quick ratio | 0.77 | 0.76 | 0.74 | 0.70 | 0.72 | 0.70 |
| Debt / assets | 85.51 | 83.60 | 83.66 | 83.30 | 79.60 | 74.48 |
| LT debt / equity | 75.01 | 77.59 | 75.58 | 76.85 | 72.99 | 70.60 |
| Interest coverage | 7.94 | 7.48 | 6.51 | 4.67 | 4.68 | 5.48 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
UnitedHealthcare76.78%
Optum Rx34.18%
Optum Health20.95%
Optum Insight4.82%
Quote time 2026-09-04 20:02:36
For reference only, not investment advice.